BAKER BROS. ADVISORS LP → BeOne Medicines Ltd. BEIGF

On June 11, 2026, Felix J. Baker, Ph.D., a managing member of the Adviser GP, was elected to the board of directors of the Issuer (the "Board") to serve as a director of the Issuer until the completion of the Issuer's 2027 annual general meeting of shareholders, subject to his earlier resignation or removal. Dr. Baker serves as the Lead Director of the Issuer. Michael Goller and Ranjeev Krishana, both previous directors of the Issuer and both of whom are employees of the Adviser, did not stand for re-election to the Board, and as a result their service on the Board automatically expired on June 11, 2026, the date of the Issuer's 2026 annual general meeting of shareholders. In conjunction with his election to the Board, Felix J. Baker was granted 18,980 restricted share units that vest solely into Ordinary Shares (each, an "RSU") on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting of the Issuer, provided, however, that all vesting of such RSUs will cease if Dr. Baker resigns from the Board or otherwise ceases to serve as a director, unless the Board determines otherwise. The Funds hold securities of the Issuer for investment purposes. The Reporting Persons or their affiliates may purchase additional securities or dispose of securities in varying amounts and at varying times depending upon the Reporting Persons' continuing assessments of pertinent factors, including the availability of ADS or Ordinary Shares or other securities for purchase at particular price levels, the business prospects of the Issuer, other business investment opportunities, economic conditions, stock market conditions, money market conditions, the attitudes and actions of the Board and management of the Issuer, the availability and nature of opportunities to dispose of securities of the Issuer and other plans and requirements of the particular entities. The Reporting Persons may discuss items of mutual interest with the Issuer's management and other investors, which could include items in subparagraphs (a) through (j) of Item 4 of Schedule 13D. Depending upon their assessments of the above factors, the Reporting Persons or their affiliates may change their present intentions as stated above and they may assess whether to make suggestions to the management of the Issuer regarding financing, and whether to acquire additional securities of the Issuer, including ADS or Ordinary Shares (by means of open market purchases, privately negotiated purchases, exercise of some or all of the options to purchase Ordinary Shares ("Share Options"), vesting of RSUs or otherwise) or to dispose of some or all of the securities of the Issuer, including ADS or Ordinary Shares, under their control. Except as otherwise disclosed herein, at the present time, the Reporting Persons do not have any plans or proposals with respect to any extraordinary corporate transaction involving the Issuer including, without limitation, those matters described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.